We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+10.71%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.54B
AUM Growth
+$321M
Cap. Flow
-$140M
Cap. Flow %
-5.5%
Top 10 Hldgs %
33.9%
Holding
112
New
21
Increased
26
Reduced
21
Closed
14

Top Buys

Rank Stock Value
1
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$105M
2
DBVT
DBV Technologies
DBVT
+$41.9M
3
LCI
Lannett Company, Inc.
LCI
+$30.8M
4
RVNC
Revance Therapeutics, Inc.
RVNC
+$28.7M
5
ELV icon
Elevance Health
ELV
+$27.7M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$79.5M
2
MCK icon
McKesson
MCK
+$49.5M
3
NXTM
NxStage Medical Inc.
NXTM
+$43.6M
4
VTRS icon
Viatris
VTRS
+$24.8M
5
PDCO
Patterson Companies, Inc.
PDCO
+$21.9M

Sector Composition

Rank Sector Weight
1 Healthcare 78.77%
2 Financials 0.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HIND
76
Vyome Holdings
HIND
$15.1M
– –
0
– –
ARLZ
77
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$2.33M 0.09%
1,644,583
– –
TARA icon
78
Protara Therapeutics
TARA
$230M
$2.33M 0.09%
30,622
– –
PFNX
79
DELISTED
Pfenex Inc.
PFNX
$2.21M 0.09%
+830,216
New +$2.3M
VYGR icon
80
Voyager Therapeutics
VYGR
$192M
$1.95M 0.08%
117,647
– –
MDXG icon
81
MiMedx Group
MDXG
$640M
$1.89M 0.07%
150,000
– –
XFOR icon
82
X4 Pharmaceuticals
XFOR
$360M
$1.68M 0.07%
+731
New +$1.85M
KIDS icon
83
OrthoPediatrics
KIDS
$494M
$1.12M 0.04%
+58,247
New +$1.11M
AKTX
84
Akari Therapeutics
AKTX
$19.3M
$1.08M 0.04%
312
-230
-42% -$887K
NCNA
85
NuCana
NCNA
$5.47M
$835K 0.03%
17
-68
-80% -$4.25M
RARX
86
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$673K 0.03%
79,150
-23,000
-23% -$283K
AXGN icon
87
Axogen
AXGN
$2.12B
– –
-344,428
Closed -$6.67M
CNC icon
88
Centene
CNC
$32.8B
– –
-204,000
Closed -$9.87M
RNAC icon
89
Cartesian Therapeutics
RNAC
$243M
– –
-31,721
Closed -$17.4M
SAGE
90
DELISTED
Sage Therapeutics
SAGE
– –
-68,000
Closed -$4.24M
SGMO
91
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-653,000
Closed -$9.79M
PDCO
92
DELISTED
Patterson Companies, Inc.
PDCO
– –
-566,000
Closed -$21.9M
ITCI
93
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-118,116
Closed -$1.86M
MRNS
94
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-338,750
Closed -$7.95M
AGRX
95
DELISTED
Agile Therapeutics
AGRX
– –
-611
Closed -$5.45M
SIOX
96
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-131,500
Closed -$7.24M
MYOV
97
DELISTED
Myovant Sciences Ltd.
MYOV
– –
-400,685
Closed -$6.2M
CMTA
98
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
– –
-462,387
Closed -$7.81M
NXTM
99
DELISTED
NxStage Medical Inc.
NXTM
– –
-1,579,285
Closed -$43.6M
AAAP
100
DELISTED
Advanced Accelerator Applications S.A.
AAAP
– –
-218,000
Closed -$14.7M
1 2 3
4

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q4 2017 Portfolio in Review

As of Q4 2017, Deerfield Management held 112 positions worth $2.54B, up 14% from $2.22B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Deerfield Management withdrew a net $140M in Q4 2017, closing 14 positions and reducing 21 holdings. Its most notable exit was NxStage Medical Inc., an estimated $43.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 76% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Revance Therapeutics, Inc. worth $35.8M.

  • Deerfield Management's largest Q4 2017 buy was Revance Therapeutics, Inc.: 1,000,000 shares worth $35.8M.
  • Deerfield Management added most to MALLINCKRODT PUBLIC LIMITED COMPANY in Q4 2017, an estimated $105M increase.
  • Deerfield Management's biggest Q4 2017 reduction was AveXis, Inc. Common Stock, cutting an estimated $79.5M.
  • Deerfield Management fully exited NxStage Medical Inc. in Q4 2017, selling an estimated $43.6M.
  • Deerfield Management's ten largest holdings make up 34% of its $2.54B portfolio in Q4 2017.
  • Deerfield Management opened 21 new positions and closed 14 in Q4 2017.
  • Deerfield Management's portfolio value rose 14% quarter-over-quarter to $2.54B.

Based on Deerfield Management's 13F filing for Q4 2017, filed 14 Feb 2018.